Posts

Dimerix acquires kidney injury drug DMX-652 from Mission Therapeutics as Arpeggio appears to wind down acute kidney program

on
Dimerix, an Australian clinical-stage biopharmaceutical company, has acquired the Phase 2-ready acute kidney injury (AKI) drug candidate DMX-652 (formerly MTX652) from UK-based Mission Therapeutics for an upfront payment of $5 million and up to $287 million in potential milestone payments, totaling up to $292 million including royalties and sales milestones. DMX-652 is a selective USP30 inhibitor that supports mitochondrial quality control in injured kidney cells and is being developed as an oral once daily capsule for the prevention of AKI, a condition with significant unmet medical need and an estimated global market of $3.5 billion in 2026. The acquisition includes the assignment of the composition-of-matter patent, an open US Investigational New Drug (IND) application, an FDA-cleared Phase 2 clinical trial protocol, and sufficient GMP drug supply for the planned study, which will evaluate DMX-652 in approximately 160 patients at high risk of AKI following cardiac surgery. Mis...

Sanofi's Sarclisa Goes Hands-Free: Will It Matter to Physicians?

on

Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador

on

Novo Nordisk and Alvotech Face Continued FDA Scrutiny at Plants Tied to Recent FDA Rejections

on

Takeda's zasocitinib proves top-notch for difficult-to-treat psoriasis in Phase 3 update

on

BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields

on

GSK axes key cough drug candidate after mixed Phase 3 data end blockbuster hopes

on

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

on

Biopharma Bites: Boehringer’s 2Q, Keytruda Expansion, and Wegovy’s Market Domination

on

Brain implants that restore touch pass decade-long safety test

on

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

on

Bipartisan Senate bill seeks to build vigilance around foreign companies making drugs in US

on

Eli Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J in psychedelic mental health market

on